DREAP

DREAP analyzes radiation-induced biological responses by estimating surviving fraction (SF), relative biological effectiveness (RBE), normal tissue complication probability (NTCP), and tumor control probability (TCP) from clonogenic assay and treatment-plan data across cell population and organ scales.

Key Features:

• Surviving Fraction (SF) Models: Incorporates five established cell population SF models to estimate SF and RBE from clonogenic assay data.
• NTCP and TCP Models: Implements two established models to calculate NTCP and TCP from radiation treatment plans.
• Quantitative Analyses and Graphical Representation: Provides quantitative analyses and graphical outputs to verify and interpret model results.
• Comparative Plan Analysis: Compares NTCP, TCP, uncomplicated TCP (UCP), and user-dependent weight-based UCP (UUCP) across up to three rival treatment plans.
• Uncertainty Verification: Verifies estimated SF, model parameters, RBE, and associated uncertainties.

Scientific Applications:

• Radiation Biology Research: Enables analysis of cellular and tissue responses to ionizing radiation using SF and RBE estimates from clonogenic assays.
• Cancer Treatment Planning: Supports evaluation and comparison of treatment plans by computing NTCP, TCP, UCP, and UUCP metrics.
• Clinical and Academic Studies: Facilitates validation and quantitative assessment of radiobiological models and therapy outcomes across tested cell lines and plans.

Methodology:

DREAP uses deterministic models validated across tested cell lines, reporting averaged mean relative errors (MREs) not exceeding 0.3% for SF models and below 0.1% for NTCP/TCP calculations, with computations for SF, RBE, NTCP, and TCP completed in under 1.5 seconds.